Jun
16
2022
Upcoming webinar

Accelerating cell therapy discovery & development with non-viral gene engineering

Thursday June 16th 2022 8:00 PDT; 11:00 EDT; 16:00 BST; 17:00 CEST

Gene engineering of immune cells has become a powerful tool for creating cellular therapies. Currently, this critical step is primarily performed using virus-based gene delivery systems (e.g. lentivirus). However, virus-based engineering methods are plagued with long lead times, inconsistent batches, low cargo capacity, and high costs.

Recently, advances in non-viral gene engineering methods, including transposon-based systems, have provided developers with an alternative gene engineering method that addresses these limitations. Utilizing a “cut-and paste” method of gene delivery, transposon-based systems are capable of stable genomic integration. TcBuster™ is one such transposon-based system and in this webinar we will present data demonstrating both T cell and NK cell gene editing using the technology.

How the mechanism of transposon-based gene engineering systems address the current challenges virus-based systems face What is TcBuster and how does it work How TcBuster compares to other delivery platforms for primary immune cells How TcBuster can be adopted into your pipeline as a research use or GMP compliant system

David Hermanson, Ph.D.

Senior Manager of R&D Applications, Cell and Gene Therapy, Bio-techne

David is the Senior Manager of R&D Applications in Cell and Gene Therapy at Bio-Techne. He works with Bio-Techne’s suite of cell and gene therapy products to establish appropriate protocols and workflows for the modification of immune cells include CAR T and CAR NK cell workflows. His career has focused on non-viral gene editing of T and NK cells using transposon systems and continues to drive the adoption of TcBuster™ for cell therapy.

Xiaobai Patrinostro, Ph.D.

Manager of Genome Engineering Services, Cell and Gene Therapy, Bio-techne

Xiaobai Patrinostro is the Manager of Genome Engineering Services in Cell and Gene Therapy at BioTechne. Xiaobai received her PhD in Molecular Biology and Biochemistry from the University of Minnesota. Xiaobai has 18 years of experience in biological sciences, 10 of which in genome engineering. Xiaobai joined BMogen BioTechnologies in 2018 which was acquired by BioTechne in 2019. Xiaobai’s work at BioTechne is focused on utilizing the TcBuster™ technology to engineer custom cell lines for clients in the Cell and Gene therapy field.

29
Days
15
Hrs
31
Min

SPEAKERS

David Hermanson
Senior Manager of R&D Applications, Cell and Gene Therapy at Bio-techne
Xiaobai Patrinostro
Manager of Genome Engineering Services, Cell and Gene Therapy at Bio-techne

You might also like

Life on a chip - vascularized micro-tumor chips for mimicking clinical...

C Hughes
Chris Hughes
Chris Hughes
CSO at Aracari Biosciences
8 Jun 2022
22
Days
7
Hrs
31
Min
Register

Applying an HPLC analytical platform for mRNA process monitoring

N Pavlin
Nejc Pavlin
Nejc Pavlin
Project Manager in Process Analytics Development at BIA Separations
7 Jun 2022
21
Days
7
Hrs
31
Min
Register

Optimizing E. Coli cell growth performance with in-line, real-time OD600...

T Buch
R Shanbaky
Tanja Buch
Tanja Buch
Technical Director at Biifactory Competence Center
Ramsey  Shanbaky
Ramsey Shanbaky
Bioprocess Applications Manger at C Technologies, Inc - a Repligen Company
1 Jun 2022
14
Days
15
Hrs
31
Min
Register

Monitoring of circulating CAR T cells

A Graband,
D Hünecke,
D Bremm
Annika Graband
Annika Graband
Product Manager, Cell Analysis Reagents at Miltenyi Biotec
Dr. Sabine Hünecke
Dr. Sabine Hünecke
Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
Dr. Melanie Bremm
Dr. Melanie Bremm
Deputy Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
31 May 2022
14
Days
7
Hrs
31
Min
Register

Manufacturing considerations for viral and non-viral platform selection

V Slepushkin,
A Noyes,
A Hagerman et al.
Vladimir Slepushkin
Vladimir Slepushkin
Global Head of Manufacturing at MedTherapy Biotech
Aaron Noyes
Aaron Noyes
Vice President of Development at Codiak Biosciences
Allison Hagerman
Allison Hagerman
Vice President, Product Development, Oncolytics Biotech
Laurens  Sierkstra
Laurens Sierkstra
Senior Director, Business Leader, Purification at Thermo Fisher Scientific
10 May 2022
Watch now